Author

Sylvia Lauks

University of Guelph

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Physiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Aditya N. BrahmbhattiD· 2 shared Bianca GarlisiiD· 2 shared Brooke A. Morris· 2 shared Caroline Aitken· 2 shared Christopher G. R. PerryiD· 2 shared Jeremy A. SimpsoniD· 2 shared Jim PetrikiD· 2 shared Leslie M. OgilvieiD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPhysiology

Aditya N. BrahmbhattORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The mitochondrial-targeted antioxidant SkQ1 prevents mitochondrial-linked apoptosis but not necroptosis or skeletal muscle atrophy in ovarian cancer

Shahrzad Khajehzadehshoushtar, Luca J. Delfinis, Fasih Ahmad Rahman, Madison C. Garibotti, Shivam Gandhi, Aditya N. Brahmbhatt, Brooke A. Morris, Bianca Garlisi, Sylvia Lauks, Caroline Aitken, Leslie M. Ogilvie, Zhu‐Xu Zhang, Jeremy A. Simpson, Joe Quadrilatero, Jim Petrik, Christopher G. R. Perry

This paper investigates the role of mitochondrial ROS in skeletal muscle atrophy during ovarian cancer and finds that SkQ1 reduces mitochondrial-linked apoptosis but not necroptosis or atrophy.

The Journal of Physiology · Nov 2, 2025Peer-reviewedPhysiology

Mitochondrial-targeted plastoquinone therapy ameliorates early onset muscle weakness that precedes ovarian cancer cachexia in mice

Luca J. Delfinis, Shahrzad Khajehzadehshoushtar, Luke D. Flewwelling, Nathaniel J. Andrews, Madison C. Garibotti, Shivam Gandhi, Aditya N. Brahmbhatt, Brooke A. Morris, Bianca Garlisi, Sylvia Lauks, Caroline Aitken, Leslie M. Ogilvie, Stavroula Tsitkanou, Jeremy A. Simpson, Nicholas Perry Greene, , Christopher G. R. Perry

This study shows mitochondrial-targeted plastoquinone SkQ1 reduces early muscle weakness in ovarian cancer mice by improving calcium handling and mitochondrial function, without preventing atrophy.

Molecular Metabolism · Jul 17, 2025Peer-reviewedPhysiology